No Data
No Data
Hybio Pharmaceutical (SZSE:300199) Pulls Back 6.7% This Week, but Still Delivers Shareholders Favorable 21% CAGR Over 3 Years
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Hybio Pharmaceutical (300199.SZ): Han Yu Dali obtained an industrial cannabis processing license through re-evaluation and replacement.
On July 18th, Gelonhui reported that Hybio Pharmaceutical (300199.SZ) recently applied for an extension to the local department and passed the on-site re-evaluation inspection of the Public Security Bureau in Dali, and finally obtained the renewal of the Industrial Cannabis Processing License in Yunnan Province.
Hybio Pharmaceutical Secures Chilean Medical Approval for Injectable Medication
Hybio Pharmaceutical (300199.SZ): Injection Terlipressin has obtained market authorization in Chile.
On July 4th, Gelunhui reported that Hybio pharmaceutical (300199.SZ) announced that recently, Shenzhen Hybio pharmaceutical co., LTD. received the approval certificate for injection terlipressin issued by the national drug management agency of Chile (ANAMED). Indications of injection terlipressin: treatment of esophageal variceal bleeding.
Hybio Pharmaceutical (300199.SZ): Hybio's Active Pharmaceutical Ingredient for Salmon Calcitonin in Wuhan has obtained the approval notice for market application.
On June 28, 2024, hybio pharmaceutical (wuhan), a wholly-owned subsidiary of Shenzhen hybio pharmaceutical co., ltd. (hereinafter referred to as hybio wuhan), received the approval letter of chemical raw materials for salmon calcitonin issued by the State Administration for drug supervision and management (acceptance number: cyhs2360154). Salmon calcitonin is one of the hormones that regulate calcium metabolism and inhibit the parathyroid gland. It can significantly reduce the loss of bone calcium in high-turnover bone diseases such as osteoporosis, dysplasia and painful neuropathic malnutrition.
No Data